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Abstract
Hyperactivation of ErbB signaling is implicated in metastatic breast cancer. However, the
mechanisms that cause dysregulated ErbB signaling and promote breast carcinoma cell invasion
remain poorly understood. One pathway leading to ErbB activation that remains unexplored in breast
carcinoma cell invasion involves transactivation by G-protein-coupled receptors (GPCRs). Protease-
activated receptor-1 (PAR1), a GPCR activated by extracellular proteases, is overexpressed in
invasive breast cancer. PAR1 is also proposed to function in breast cancer invasion and metastasis,
but how PAR1 contributes to these processes is not known. In this study, we report that proteolytic
activation of PAR1 by thrombin induces persistent transactivation of EGFR and ErbB2/HER2 in
invasive breast carcinoma, but not in normal mammary epithelial cells. PAR1-stimulated EGFR and
ErbB2 transactivation leads to prolonged extracellular signal-regulated kinase-1 and −2 signaling
and promotes breast carcinoma cell invasion. We also show that PAR1 signaling through Gαi/o and
metalloprotease activity is critical for ErbB transactivation and cellular invasion. Finally, we
demonstrate that PAR1 expression in invasive breast carcinoma is essential for tumor growth in
vivo assessed by mammary fat pad xenografts. These studies reveal a critical role for PAR1, a receptor
activated by tumor-generated proteases, in hyperactivation of ErbB signaling that promotes breast
carcinoma cell invasion.
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Introduction
The molecular mechanisms underlying breast tumorigenesis, invasion and metastasis remain
poorly understood. One pathway implicated in metastatic breast cancer and associated with
poor clinical prognosis involves hyperactivation of ErbB signaling (Yarden, 2001). The ErbB
family of receptor tyrosine kinases includes epidermal growth factor (EGF) receptor (EGFR)/
ErbB1, ErbB2/HER2, ErbB3 and ErbB4. ErbB family members undergo ligand-induced
dimerization, which provokes intrinsic kinase activation, transphosphorylation of cytoplasmic
tyrosine residues and recruitment of signaling molecules. ErbB2/HER2 is overexpressed in
~20–30% of human invasive breast cancers and is correlated with increased metastatic potential
and decreased patient survival (Cobleigh et al., 1999). Increased expression of EGFR and
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ErbB3 is also correlated with reduced breast cancer patient survival (Nicholson et al., 2001;
Witton et al., 2003). ErbB2 does not bind ligand directly but exists in an extended conformation
poised to signal by forming heterodimeric complexes with EGFR or ErbB3 (Burgess et al.,
2003; Garrett et al., 2003). Humanized antibodies generated against ErbB2/HER2 termed
trastuzumab or Herceptin reduce ErbB2 activity and expression at the cell surface and increase
survival of patients with metastatic breast cancer (Cobleigh et al., 1999; Slamon et al., 2001).
However, many patients who achieve initial response to trastuzumab-based therapies acquire
resistance and many ErbB2/HER2-positive breast cancers do not respond to trastuzumab
treatments (Nahta and Esteva, 2007). Thus, identifying other pathways that lead to
hyperactivation of ErbB signaling is critical for identifying new drug targets and for improving
treatment options for patients with metastatic breast cancer disease.
One pathway leading to ErbB signaling that has not been thoroughly investigated in breast
cancer progression involves transactivation by G-protein-coupled receptors (GPCRs) (Wetzker
and Bohmer, 2003). Transactivation of EGFR by GPCRs results from the activation of a
disintegrin and metalloprotease (ADAM) and/or matrix metalloprotease (MMP) family
members, which release membrane-anchored ligands such as heparin-binding-EGF or
transforming growth factor-α (TGF-α) and through intracellular signaling pathways (Prenzel
et al., 1999; Gschwind et al., 2003). Previous studies have shown that several GPCR agonists
including thrombin are capable of inducing transactivation of EGFR in both transformed and
nontransformed cells (Daub et al., 1996; Prenzel et al., 1999; Darmoul et al., 2004; Bergman
et al., 2006). GPCR-mediated transactivation of EGFR through release of membrane-anchored
ligands also functions in various pathophysiological diseases, including kidney deterioration,
cardiac hypertrophy and cardioprotection (Asakura et al., 2002; Lautrette et al., 2005; Noma
et al., 2007). However, the role of GPCR-mediated ErbB transactivation in breast carcinoma
cell invasion has not been previously investigated.
Protease-activated receptor-1 (PAR1), a GPCR uniquely activated by proteolysis, has been
implicated in invasive and metastatic breast cancer (Vu et al., 1991; Arora et al., 2007). PAR1
elicits cellular responses to multiple tumor-generated proteases, including plasmin, MMP-1
and coagulant proteases (Kuliopulos et al., 1999; Boire et al., 2005). An increase in PAR1
expression is positively correlated with invasiveness of primary breast tissue specimens and
breast carcinoma cell lines (Even-Ram et al., 1998; Booden et al., 2004). Moreover, the ectopic
expression of PAR1 in noninvasive MCF7 breast carcinoma is sufficient to promote tumor
growth and invasion in a xenograft nude mouse model (Boire et al., 2005). Activated PAR1
also fails to downregulate in invasive breast carcinoma and consequently signals persistently
to extracellular signal-regulated kinase-1 and -2 (ERK1/2) and promotes breast carcinoma
invasion (Booden et al., 2004). The mechanism by which activated PAR1 induces prolonged
ERK1/2 signaling and cellular invasion is not known.
In this study, we report that proteolytic activation of PAR1 by thrombin causes persistent
transactivation of EGFR and ErbB2 that sustains ERK1/2 signaling and promotes breast
carcinoma cell invasion. PAR1 expression in breast carcinoma is also essential for tumor
growth in vivo. These findings reveal a critical role for PAR1 in mediating hyperactivation of
ErbB signaling that promotes breast carcinoma cell invasion.
Results
EGFR and ErbB2/HER2 transactivation by PAR1
To understand the contribution of PAR1 to processes that lead to breast carcinoma invasion
and metastasis, we first examined whether thrombin transactivates EGFR in invasive breast
carcinoma. MDA-MB-231 cells were incubated with thrombin for various times at 37 °C and
EGFR tyrosine phosphorylation was assessed. Thrombin caused a ~3-fold increase in EGFR
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tyrosine phosphorylation at 2 min that remained elevated over a 10 min time course (Figure
1a), consistent with the early increase in thrombin-stimulated EGFR transactivation previously
observed in multiple cell types (Daub et al., 1996; Prenzel et al., 1999). Reciprocal
immunoprecipitation experiments revealed a similar early increase in EGFR tyrosine
phosphorylation following thrombin incubation (Figure 1a). The PAR1-specific agonist
peptide TFLLRNPNDK also induced EGFR transactivation in a manner comparable to that
observed with thrombin (Supplementary Figure 1a).
ErbB2 is overexpressed in metastatic breast carcinoma and signals by forming heterodimeric
complexes with EGFR or ErbB3; raising the possibility that thrombin might induce ErbB2
transactivation in invasive breast carcinoma. Remarkably, thrombin stimulated an ~2-fold
increase in ErbB2 tyrosine phosphorylation at 2 min that was sustained for 10 min in MDA-
MB-231 cells (Figure 1b). ErbB2 transactivation by thrombin was also confirmed in reciprocal
immunoprecipitation experiments (Figure 1b). The PAR1-specific agonist peptide
TFLLRNPNDK also stimulated ErbB2 transactivation with a magnitude and duration similar
to that observed with thrombin (Supplementary Figure 1b). These studies are the first to
demonstrate thrombin-induced ErbB2 transactivation in invasive breast carcinoma.
To directly test whether PAR1 mediates thrombin-induced ErbB transactivation, we used
MDA-MB-231 breast carcinoma cells deficient in endogenous PAR1 expression. MDA-
MB-231 cells expressing a short-hairpin loop PAR1 (P1) small interfering RNA (siRNA)
showed a substantial reduction in PAR1 cell surface expression compared to control cells or
cells stably transduced with PAR2-specific P2 short hairpin RNA (shRNA) (Figure 1c).
Thrombin- and TFLLRNPNDK-stimulated phosphoinositide hydrolysis were also virtually
abolished in P1 shRNA-expressing cells compared to control cells (Figure 1c), whereas
signaling induced by the PAR2-selective peptide agonist SLIGKV remained intact. Together
these findings are consistent with a loss of functional PAR1 in P1 shRNA-expressing MDA-
MB-231 cells.
We next assessed thrombin-induced ErbB transactivation in PAR1-deficient MDA-MB-231
cells. Thrombin stimulated an ~2-fold increase in EGFR tyrosine phosphorylation in control
cells but failed to induce EGFR transactivation in PAR1-deficient cells (Figure 1d). In contrast,
addition of EGF ligand caused a robust increase in EGFR tyrosine phosphorylation in P1
shRNA-expressing cells (Figure 1d), indicating that EGFR activity remained intact in PAR1-
deficient cells. Thrombin-stimulated ErbB2 transactivation was also completely inhibited in
PAR1-deficient cells compared to control cells (Figure 1d). We also found that MDA-MB-231
cells express PAR1 and PAR2, but not other PARs, consistent with a role for PAR1 in thrombin-
stimulated responses (Supplementary Figure 2). Together, these data strongly suggest a critical
role for PAR1, and not another receptor or factor, in thrombin-induced EGFR and ErbB2
transactivation in invasive breast carcinoma cells.
EGFR kinase activity is required for thrombin-induced ErbB transactivation
To determine whether EGFR kinase activity is required for thrombin-stimulated ErbB
transactivation we used the tyrphostin AG1478 compound, a selective EGFR kinase inhibitor.
AG1478 substantially inhibited EGF-induced EGFR tyrosine phosphorylation (Figure 2a,
lanes 5–6), consistent with inhibition of EGFR kinase activity. EGF-stimulated ErbB2 tyrosine
phosphorylation was also blocked by AG1478 (Figure 2b, lanes 5 and 6), suggesting that EGFR
kinase activity mediates ErbB2 transphosphorylation. AG1478 also caused marked inhibition
of EGFR and ErbB2 tyrosine phosphorylation induced by thrombin (Figure 2a and b, lanes 1–
4). These findings reveal a critical role for EGFR kinase activity in thrombin-induced EGFR
and ErbB2 transactivation in invasive breast carcinoma. Similar effects were observed with
the PD153035 compound, another specific inhibitor of EGFR kinase activity (data not shown).
However, neither AG1478 nor PD153035 affected PAR1-stimulated phosphoinositide
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hydrolysis, excluding the possibility of global inhibitor effects on PAR1 function (Figure 2c).
Thus, EGFR tyrosine kinase activity is critical for thrombin-stimulated EGFR and ErbB2
transactivation in highly invasive breast carcinoma cells.
Thrombin induces persistent ErbB transactivation in invasive breast carcinoma
Hyperactivation of ErbB signaling is associated with invasive breast cancer (Yarden, 2001).
To determine whether activation of ErbB2 signaling by thrombin is dysregulated in invasive
breast carcinoma we examined the kinetics of ErbB transactivation. In MDA-MB-231 cells,
thrombin caused prolonged EGFR and ErbB2 transactivation that was detected as early as 2
min and remained markedly sustained for at least 2 h (Figure 3a). A similar rapid and persistent
increase in EGFR and ErbB2 tyrosine phosphorylation induced by thrombin was observed in
invasive BT549 breast carcinoma (Figure 3b). In contrast, in normal human mammary
epithelial cells (HMECs) thrombin elicited a transient increase in EGFR and ErbB2
transactivation, which peaked at 5 min and was substantially diminished by 1 h (Figures 3c
and d). These results suggest that proteolytic activation of PAR1 induces persistent ErbB
signaling in invasive breast carcinoma but not in normal breast epithelial cells. Moreover, the
extent of ErbB2 transactivation stimulated by thrombin was comparable to that induced by
saturating concentrations of EGF ligand (Figure 3e). These data suggest that the persistent
ErbB2 transactivation induced by thrombin occurs through a highly efficient mechanism in
invasive breast carcinoma.
PAR1 promotes ERK1/2 signaling and breast carcinoma invasion through ErbB
transactivation
We previously showed that PAR1 is not downregulated and signals persistently to ERK1/2 in
invasive breast carcinoma (Booden et al., 2004). To examine the role of EGFR and ErbB2
transactivation to PAR1-mediated ERK1/2 activation, we used AG1478 to inhibit EGFR kinase
activity and siRNA to deplete cells of ErbB2 expression. In control cells, the PAR1-specific
agonist peptide increased ERK1/2 activity within 15 min that remained elevated for 6 h (Figure
4a), consistent with that previously reported (Booden et al., 2004). The sustained activation of
ERK1/2 induced by activated PAR1 was considerably reduced by AG1478 (Figure 4a). We
next used siRNA-targeting ErbB2 to assess the role of ErbB2 in PAR1-induced ERK1/2
activation. MDA-MB-231 cells electroporated with ErbB2 siRNA showed a substantial
reduction in ErbB2 expression compared to nonspecific siRNA control cells (Figure 4b, inset).
The early increase in ERK1/2 activity induced by agonist peptide was diminished but still
detectable in ErbB2 siRNA-treated cells, whereas the sustained ERK1/2 activity was
considerably inhibited (Figure 4b). Thus, EGFR and ErbB2 transactivation induced by
thrombin contributes to prolonged ERK1/2 signaling in invasive breast carcinoma.
We next examined the contribution of EGFR transactivation to thrombin-induced breast
carcinoma invasion. MDA-MB-231 cells were treated with varying concentrations of thrombin
to determine the optimal dose for inducing cellular invasion. We found that low thrombin
concentrations induced significant increases in breast carcinoma cell invasion compared to
untreated control cells, whereas higher thrombin concentrations actually inhibited cellular
invasion (Figure 4c). These findings suggest that the extent of PAR1 activation is important
for conferring positive or negative regulation of cellular invasion. We then examined the
capacity of thrombin to induce cellular invasion following inhibition of EGFR kinase activity
with AG1478. Thrombin-induced a significant increase in invasion of control cells, which was
markedly inhibited by AG1478 (Figure 4d). These studies are the first to demonstrate a critical
role for EGFR transactivation in thrombin-induced breast carcinoma cell invasion.
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PAR1 signaling through Gαi/o and metalloprotease activity mediate ErbB transactivation and
breast carcinoma cell invasion
To define the mechanism by which PAR1 stimulates ErbB transactivation we examined the
function of Gαi/o using pertussis toxin, which catalyses ADP ribosylation and inactivation of
Gαi/o proteins. Thrombin-induced EGFR transactivation was substantially diminished in
MDA-MB-231 cells pretreated with pertussis toxin compared to control cells (Figure 5a).
ErbB2 transactivation induced by thrombin was also virtually ablated in pertussis toxin-treated
cells (Figure 5b). These findings are consistent with a critical role for Gαi/o signaling in
thrombin-induced ErbB transactivation in invasive breast carcinoma.
To determine whether PAR1-stimulated EGFR and ErbB2 transactivation occurred in a
metalloprotease-dependent manner we used the broad-spectrum metalloprotease inhibitor
GM6001. EGFR transactivation induced by thrombin was substantially inhibited in cells
treated with active GM6001 compared to inactive agent or vehicle control-treated cells (Figure
6a). Thrombin-stimulated ErbB2 transactivation was similarly inhibited by GM6001
pretreatment compared to control cells (Figure 6b). We next examined whether thrombin-
induced cellular invasion was dependent on metalloprotease activity. Thrombin stimulated an
~2-fold increase in MDA-MB-231 cellular invasion under control conditions that was virtually
abolished in GM6001-treated cells (Figure 6c). To identify the ErbB ligands released by MDA-
MB-231 cells in response to thrombin, we used heparin and the diphtheria toxin mutant
CRM197. Both EGFR and ErbB2 transactivation induced by thrombin were virtually ablated
following preincubation with heparin and CRM197 (Figure 6d), suggesting that HB-EGF is
the critical mediator of this process. These studies strongly suggest a critical role for
metalloprotease activity in thrombin-induced ErbB transactivation and breast carcinoma cell
invasion.
PAR1 expression is essential for ErbB transactivation and cellular invasion induced by
fibroblasts secreted factors in vitro and for tumor growth in vivo
Stromal factors secreted into the tumor microenvironment promote tumor progression.
Previous studies have also demonstrated that breast carcinoma invasion toward factors secreted
by stromal fibroblasts is positively correlated with increased PAR1 expression (Even-Ram et
al., 1998). We therefore examined whether PAR1 is necessary for transactivation of ErbB
induced by factors secreted by NIH 3T3 fibroblasts. PAR1-deficient breast carcinoma
exhibited a significant reduction in invasion toward conditioned medium compared to control
cells (Figure 7a), suggesting a critical role for PAR1 in cellular invasion induced by factors
secreted by fibroblasts. We next examined whether fibroblast-secreted factors induced ErbB
trans-activation through a PAR1-dependent mechanism. Interestingly, our results indicate that
NIH 3T3 fibro-blast-conditioned medium stimulated EGFR and ErbB2 transactivation
comparable to that induced by thrombin (Figures 7b and c). In contrast, conditioned medium
failed to stimulate EGFR and ErbB2 transactivation in cells lacking PAR1 (Figures 7b and c).
However, EGF-induced EGFR tyrosine phosphorylation remained intact. Thus, in addition to
thrombin, factors secreted by fibroblasts present in conditioned media induce ErbB
transactivation through a PAR1-dependent mechanism.
Our in vitro studies strongly suggest an important role for PAR1 in thrombin-induced ErbB
transactivation and breast carcinoma cell invasion. To determine whether PAR1 contributes to
breast carcinoma invasion in vivo, we examined the ability of PAR1-deficient cells to confer
tumor growth and invasion using an orthotopic mammary fat pad xenograft model in
immunodeficient mice. MDA-MB-231 cells implanted into the mouse mammary fat pad
generate tumors and develop metastases with a high frequency (Price et al., 1990). PAR1-
deficient and control cells were implanted into the left and right mammary fat pads, respectively
of 6-to 8-week-old female immunodeficient mice and tumor growth was measured weekly.
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Tumor nodules were present in all mice implanted with cells within 1 week. Surprisingly,
however, PAR1-deficient cells showed a significant reduction in tumor growth compared to
control cells measured over a 6-week period. In addition, hematoxylin and eosin (H&E)
staining of tumor sections prepared 6-weeks postimplantation revealed invasive growth of
control cells (Figure 7d), whereas tumor growth and invasion was not detected in sections
derived from sites implanted with PAR1-deficient cells. Similarly, PAR1-deficient cells
displayed attenuated tumor growth compared to vector control cells examined by subcutaneous
flank injection using immunodeficient mice (data not shown). These studies are the first to
demonstrate a critical role for PAR1 in tumor growth in a mammary fat pad xenograft model
using immunodeficient mice.
Discussion
In the present study, we demonstrate that proteolytic activation of PAR1 by thrombin induces
persistent EGFR and ErbB2 transactivation in invasive breast cancer cells, which is distinct
from transient EGFR and ErbB2 transactivation observed in normal mammary epithelial cells.
We also show that PAR1-stimulated EGFR and ErbB2 transactivation sustains ERK1/2
signaling and promotes breast carcinoma invasion. In addition, PAR1 signaling through
Gαi/o and metalloprotease activity is critical for transactivation of EGFR and ErbB2 and
induction of cellular invasion. Interestingly, transactivation of ErbB2 induced by thrombin
occurred to a similar extent, as that observed with EGF ligand, indicating that GPCR
transactivation of ErbB2 is an efficient mode of activation in invasive breast carcinoma.
Finally, we report that PAR1 expression in breast carcinoma is essential for tumor growth in
vivo, suggesting a critical function for PAR1 in processes that promote breast cancer
progression. Thus, our study establishes an important link between PAR1, a receptor activated
by tumor-generated proteases, and hyperactivation of ErbB signaling that contribute to
processes associated with progression of metastatic breast cancer.
Overexpression of ErbB2/HER2 leads to hyperactivation of ErbB signaling and is implicated
in metastatic breast cancer disease (Yarden, 2001; Burgess et al., 2003). However, the
mechanism(s) that lead to activation of ErbB signaling in breast cancers are varied and poorly
understood. Our study establishes an important role for PAR1 in mediating persistent activation
of ErbB signaling in invasive breast carcinoma. ErbB2 does not signal alone, but preferentially
forms heterodimeric signaling complexes with EGFR or ErbB3 (Yarden, 2001; Burgess et
al., 2003). Strikingly, proteolytic activation of PAR1 by thrombin is sufficient to activate and
sustain ErbB2 signaling through a mechanism that requires EGFR activation. This is consistent
with ErbB2 heterodimerization with EGFR to form a potent signaling complex. We show that
thrombin-induced ErbB2 transactivation is dependent on EGFR kinase activity,
metalloprotease activity and release of HB-EGF ligand. Moreover, expression of ErbB3,
another preferred binding partner of ErbB2, was not detectable in MDA-MB-231 cells (data
not shown). Thus, thrombin-induced EGFR transactivation is critical for activation of ErbB2,
a receptor that cannot bind ligand directly. We also report that thrombin-induced ErbB2
transactivation is comparable to that stimulated by EGF ligand. These findings suggest that
proteolytic activation of PAR1 by thrombin is capable of efficient ErbB2 activation through a
process that requires EGFR activation. Our studies further reveal that EGFR activity is critical
for thrombin-induced breast carcinoma invasion.
The mechanism by which PAR1 persistently transactivates EGFR and ErbB2 in invasive breast
cancer cells involves Gαi/o signaling, metalloprotease activity and release of HB-EGF ligand.
We show that inactivation of Gαi/o with pertussis toxin inhibits thrombin-induced EGFR and
ErbB2 transactivation, consistent with a role for Gαi and Gβγ signaling to metalloproteases.
GPCRs regulate metalloprotease-dependent EGFR transactivation through multiple pathways,
including increases in intracellular Ca2+, activation of protein kinase C, generation of reactive
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oxygen species and the activation of the nonreceptor tyrosine kinases Src and Pyk2 (Ohtsu et
al., 2006). A previous study demonstrated that two metalloproteases ADAM15 and ADAM
17 (also known as TACE) mediate release of HB-EGF and EGFR transactivation following
thrombin stimulation (Hart et al., 2005). However, the role of these effectors in ErbB2
transactivation was not examined. Finally, we previously demonstrated that activated PAR1
trafficking is severely altered in metastatic breast carcinoma but not in nonmetastatic or normal
breast epithelial cells (Booden et al., 2004). Consequently, the proteolytically activated PAR1
is not downregulated and signals continuously to multiple effectors that likely mediate
persistent ErbB transactivation.
In addition to Gαi/o, PAR1 may signal through other G-protein subtypes to promote breast
carcinoma invasion and metastasis. Kelley et al. (2006) recently showed that the Gα12 proteins
are upregulated in invasive breast tissue specimens and that constitutively active forms of
Gα12 and Gα13 promote invasion of MDA-MB-231 and BT549 cells. These studies further
showed that thrombin-induced breast carcinoma invasion was dependent on Gα12 proteins and
Rho activation. Thus, Gα12 proteins and Rho signaling have critical functions in invasive
processes mediated by PAR1. These findings also raise the possibility that Gα12 proteins and
Rho signaling may also be important mediators of ErbB transactivation induced by PAR1.
Thrombin-induced ErbB transactivation could also mediate Rho activation to promote breast
carcinoma invasion. Thus, the function of Gα12 proteins and Rho signaling in thrombin-
induced ErbB transactivation in invasive breast carcinoma will be important to determine.
Our in vitro studies provide an important link between PAR1 and hyperactivation of ErbB
signaling, which promote breast carcinoma invasion. Intriguingly, our in vivo work also
indicates a critical role for PAR1 in breast tumor growth. Previous studies have reported that
ectopic expression of PAR1 in noninvasive MCF-7 breast carcinoma is sufficient to induce
tumor growth (Boire et al., 2005) and that anti-sense reduction of PAR1 expression in
melanoma cells causes an attenuation of tumor growth in vivo (Salah et al., 2007). However,
the mechanism by which PAR1 regulates breast tumor growth and the contribution of ErbB
transactivation in vivo is not known. Interestingly, Borrell-Pages et al., 2003 previously showed
that TACE/ADAM17 is overexpressed in human breast tumors and mediates TGF-α shedding,
which contributes to breast tumor formation in vivo. PAR1 also has been shown to activate
TACE/ADAM17 in breast cancer cell lines (Hart et al., 2005), but whether this pathway is
involved in PAR1-mediated tumor growth remains to be determined. Previous in vivo studies
have also demonstrated important roles for transactivation of ErbB family members by GPCRs
in several pathophysiological conditions, including kidney diseases, cardiac hypertrophy and
cardioprotection (Asakura et al., 2002; Lautrette et al., 2005; Noma et al., 2007). Together
these studies indicate that ErbB transactivation by PAR1 could have significant function in
several different pathophysiologies including breast cancer progression.
Our study establishes a critical function for PAR1 in persistent activation of ErbB signaling in
invasive breast carcinoma. We found that proteolytic activation of PAR1 by thrombin in
invasive breast carcinoma is critical for ErbB transactivation and cellular invasion in vitro.
PAR1 expression in invasive breast carcinoma is also essential for tumor growth in vivo. These
results strongly suggest a critical role for PAR1 in breast tumorigenesis and invasion. Further
studies to define the function of PAR1 to tumor progression and metastasis in vivo will provide
new insights into the molecular basis of breast cancer disease and provide new targets for
anticancer drug discovery.
Arora et al. Page 7















α-Thrombin was from Enzyme Research Laboratories. The agonist peptides, TFLLRNPNDK
(PAR1 specific) and SLIGKV (PAR2 specific), were synthesized as the carboxyl amide and
purified by reverse-phase high-pressure liquid chromatography (UNC Peptide Facility, Chapel
Hill, NC, USA). EGF, heparin and diphtheria toxin cross-reacting material CRM 197 were
from Sigma. AG1478, PD153035 and GM6001 compounds were from Calbiochem. Pertussis
toxin was from List Biological Laboratories Inc.
Anti-ErbB2 antibody was from LabVision Corporation. Anti-EGFR polyclonal antibody was
a gift from H Shelton Earp III (UNC, Chapel Hill, NC, USA). Anti-phosphotyrosine antibody
(PY99) was from Santa Cruz Biotechnology. Monoclonal anti-phospho-p44/42 mitogen-
activated protein kinase (MAPK) antibody and polyclonal anti-p44/42 MAPK antibody were
from Cell Signaling Technology Inc. The anti-PAR1 polyclonal antibody was generated as
described (Paing et al., 2006). Horseradish peroxidase-conjugated goat anti-mouse and goat
anti-rabbit antibodies were from Bio-Rad.
Cell lines
MDA-MB-231, BT549 and NIH 3T3 cells were obtained from American Type Culture
Collection (Manassas, VA, USA) and maintained according to their instructions. HMECs
immortalized with human telomerase reverse transcriptase were maintained in HuMEC
medium containing HuMEC Supplement Kit (growth factors, hydrocortisone, isoproterenol,
transferrin, insulin and bovine pituitary extract) purchased from Invitrogen.
MDA-MB-231 cells expressing P1 and P2 shRNA were generated as follows. The shRNA
specific for PAR1 (termed P1) or PAR2 (termed P2) were generated by insertion of an shRNA
encoding either the PAR1-specific mRNA sequence 5′-AGAUUAGUCUCCAUCAAUA-3′
and PAR2-specific mRNA sequence 5′-GGAAGAAGCCUUAUUGGUA-3′ into pSilencer
5.1-U6 Retro (Ambion Inc.) using the Bam HI and Hind III sites. The insertion sequence was
confirmed by dideoxy sequencing. Retroviruses were generated using the PA317 packaging
cells and were used to infect MDA-MB-231 cells. Mass populations of cells stably transduced
with pSilencer 5.1 encoding shRNA were selected with 0.6 µg/ml of puromycin.
Immunoprecipitation and immunoblotting
Cells grown in 10 cm2 dishes were serum starved. After various treatments, cells were lysed
in buffer containing 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH
7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 10 mM NaPP, 10 mM NaF
with freshly added 2 mM sodium orthovanadate, 1 mM phenylmethylsulphonylfluoride and
protease inhibitor cocktail. Equivalent amounts of cell lysates were immunoprecipitated with
various antibodies. Immunoprecipitates were resolved on 9% SDS-polyacrylamide gel
electrophoresis, transferred to membranes, immunoblotted and developed with enhanced
chemiluminescence (Amersham) and quantified by densitometry. Total cellular lysates were
analysed as described above.
ERK1/2 activity was determined from serum-starved cells plated at 6 × 104 cells per well in
24-well dishes. Cells were lysed in ×2 sample buffer and processed as described above.
Activated ERK1/2 was detected by immunoblotting with anti-phospho-p44/42 MAPK
(ERK1/2) antibody. Membranes were stripped and reprobed with anti-p44/42 MAPK
(ERK1/2) antibody. Immunoblots were quantitated by densitometry.
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Small interfering RNA electroporation
The following siRNA sequences targeting nonspecific 5′-CTACGTCCAGGAGCGCACC-3′
or ErbB2 mRNA sequence 5′-AAAUUCCAGUGGCCAUCAA-3′ were obtained from
Dharmacon Inc. and introduced into MDA-MB-231 cells by electroporation as described
(Morris et al., 2006).
Phosphoinositide hydrolysis
MDA-MB-231 cells were plated at 6×104 cells per well in 24-well plates. Cells labeled
overnight with 1 µCi/ml of myo-[3H]inositol (American Radiolabeled Chemicals) and
accumulated [3H]inositol phosphates were measured as described (Paing et al., 2002).
Cell surface ELISA
Cells plated at 1.6 × 105 cells per well of 24-well dishes were fixed and processed as previously
described (Morris et al., 2006).
Invasion assays
Serum-starved MDA-MB-231 cells (1.5 × 105) were added together with agonists to the upper
chamber of matrigel-coated transwells in a 24-well format (8-µm pore size polycarbonate filter;
BD Biosciences) and incubated for ~40 h at 37 °C. The bottom chamber contained 5-µg/ml
fibronectin diluted in 700 µl of NIH 3T3 fibroblast-conditioned media. Cells were then fixed,
stained with 0.4% crystal violet and noninvading cells were removed as described (Morris et
al., 2006). At least five fields of invaded cells were photographed at × 10 magnification using
an Olympus IX71 inverted microscope fitted with a UPlanFl × 10 objective and a Hamamatsu
ORCA-ER digital camera and counted.
Conditioned media
NIH 3T3 fibroblast-conditioned media was prepared from exponentially growing cells
maintained in phenol red-free Dulbecco’s modified Eagle’s medium containing 10 mM
HEPES, pH 7.4 and 1 mg/ml bovine serum albumin for 24 h. Conditioned media was collected,
aliquoted and stored at −20 °C.
Orthotopic mammary fat pad xenografts
Four- to six-week-old female ICR-severe combined immunodeficiency (SCID) mice were
obtained from Taconic (German-town, NY, USA) and maintained in a pathogen-free
environment. All animal studies were carried out in accordance with Institutional Animal Care
and Use Committee guidelines. Groups of three to four mice received two mammary fat pad
inoculations consisting of 2 × 106 control and P1 shRNA-expressing cells resuspended in 50
µl media and mixed with equal volume of matrigel. Cells were implanted orthotopically into
the left and right intact fourth inguinal mammary fat pad of 6- to 8-week-old female SCID
mice. The growth of mammary fat pad tumors was measured weekly with calipers. Tumors
were excised from the killed mice 6-weeks postimplantation, formalin fixed and embedded in
paraffin for sectioning. The UNC Lineberger Comprehensive Cancer Center Animal
Histopathology Core Facility performed the embedding, sectioning and H&E staining.
Data analysis
Data were analysed using Prism 3.0 software and statistical significance was determined using
InStat 3.0 (GraphPad, San Diego, CA, USA). Group comparisons were made using an unpaired
t-test. Final composite images were created with Photoshop 7.0 (Adobe).
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Protease-activated receptor-1 (PAR1) is essential for thrombin-induced ErbB transactivation
in breast carcinoma cells. Serum-deprived MDA-MB-231 cells were incubated with 10 nM
thrombin (a and b) for various times at 37 °C. Cells were lysed, immunoprecipitated with anti-
PY99 antibody and immunoblotted with anti-epidermal growth factor (EGF) receptor (EGFR)
or anti-ErbB2 antibody. Total cell lysates were immunoblotted for EGFR or ErbB2 as a control.
The time-course of thrombin-induced EGFR and ErbB2 transactivation shown is from a
representative experiment. The data (mean ± s.e.) are expressed as fold increase over basal
from three independent experiments. In reciprocal experiments, serum-deprived MDA-
MB-231 cells were incubated with 10 nM thrombin for 4 min at 37 °C, lysed and
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immunoprecipitated with anti-EGFR or anti-ErbB2 antibodies and then immunoblotted with
anti-PY99 antibody. (c) Control, P1 and P2 shRNA-expressing MDA-MB-231 cells were
incubated with anti-PAR1 antibody or preimmune serum, fixed and the amount of antibody
bound to the cell surface was measured by enzyme-linked immunosorbent assay (ELISA). The
data (mean ± s.d., n = 3) shown are from a representative experiment repeated at least three
times. MDA-MB-231 control and P1 shRNA cells labeled with myo-[3H]inositol were
incubated in the absence or presence of 10 nM thrombin, 100 µM TFLLRNPNDK or 100 µM
SLIGKV for 60 min at 37 °C and the amounts of [3H]inositol phosphates generated were then
measured. The data (mean ± s.d., n = 3) are expressed as fold increase over untreated control
and are representative of three different experiments. (d) Control and PAR1-deficient P1
shRNA-expressing MDA-MB-231 cells were incubated in the absence or presence of 10 nM
thrombin or 16 nM EGF for 4 min at 37 °C, lysed and immunoprecipitated with anti-PY99
antibody and immunoblotted with anti-EGFR or anti-ErbB2 antibody. Cell lysates were
immunoblotted for EGFR or ErbB2 as a control. The data are expressed as fold increase over
untreated control and are representative of three independent experiments.
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Thrombin-induced epidermal growth factor (EGF) receptor (EGFR) and ErbB2 transactivation
requires EGFR kinase activity. (a and b) MDA-MB-231 cells were pretreated with 0.1%
dimethyl sulfoxide (DMSO) or 2 µM AG1478 for 2 h at 37 °C. Cells were then incubated with
or without 10 nM thrombin or 16 nM EGF for 4 min at 37 °C and EGFR and ErbB2 tyrosine
phosphorylation was detected as described in Figure 1. The data are expressed as fold increase
over untreated control and are representative of three independent experiments. (c) MDA-
MB-231 cells labeled with myo-[3H]inositol were incubated with 0.1% DMSO, 2 µM AG1478
or 1 µM PD153035 for 2 h at 37 °C. Cells were then stimulated with 100 µM TFLLRNPNDK
for 60 min at 37 °C and the amounts of [3H]inositol phosphates generated were then measured.
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Persistent transactivation of epidermal growth factor (EGF) receptor (EGFR) and ErbB2
induced by thrombin in invasive breast carcinoma. Serum-starved MDA-MB-231 cells (a),
BT549 cells (b) and normal human mammary epithelial cells (HMECs) (c) were incubated
with 10 nM thrombin various times at 37 °C. Cells were lysed and EGFR and ErbB2 tyrosine
phosphorylation were detected as described in Figure 1. (d) The data shown are from the
thrombin treated 120 min time point and is expressed as the fold increases over untreated
control. (e) MDA-MB-231 cells were incubated in the absence or presence of 10 nM thrombin
or 16 nM EGF for 4 min at 37 °C and EGFR and ErbB2 tyrosine phosphorylation was examined.
The data shown are representative of at least three independent experiments.
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Protease-activated receptor-1 (PAR1)-stimulated epidermal growth factor (EGF) receptor
(EGFR) and ErbB2 transactivation contributes to sustained extracellular signal-regulated
kinase-1 and -2 (ERK1/2) signaling and promotes breast carcinoma cell invasion. (a) MDA-
MB-231 cells were pretreated with 0.1% dimethyl sulfoxide (DMSO) or 2 µM AG1478 for 2
h at 37 °C and then incubated with 100 µM TFLLRNPNDK for various times at 37 °C. Cell
lysates were immunoblotted with anti-phospho-p44/42 mitogen-activated protein kinase
(MAPK) (ERK1/2) antibody. Membranes were stripped and reprobed with anti-p44/42 MAPK
(ERK1/2) to control for loading. The data (mean ± s.e.) shown are expressed as fold increase
over basal from at least three independent experiments. (b) MDA-MB-231 cells were
electroporated with 600 nM ErbB2-specific or nonspecific siRNA. After 48 h, serum-deprived
cells were incubated with or without 100 µM TFLLRNPNDK for various times at 37 °C and
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ERK1/2 activity was measured and quantified as described above. The inset confirms the loss
of ErbB expression in ErbB2 siRNA-treated cells as detected by immunoblotting. (c) Serum-
starved MDA-MB-231 cells were left untreated or treated with varying concentrations of
thrombin at 37 °C and then added to the upper well and cellular invasion toward NIH 3T3-
conditioned medium (CM) was assessed. Representative data from one experiment is shown.
(d) MDA-MB-231 cells were pretreated with 0.1% DMSO or 2 µM AG1478 for 30 min at 37
°C. After the treatment, cells were incubated in the absence or presence of 1 pM thrombin and
then added the upper well and cellular invasion toward NIH 3T3 fibroblast-CM present in the
lower well with or without AG1478 was assessed. The data (mean ± s.e.) shown are expressed
as fold increase over untreated control from three independent experiments. The difference
between thrombin-stimulated cellular invasion in control and AG1478-treated cells was
significant (***P<0.005).
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Protease-activated receptor-1 (PAR1) signaling through Gαi/o is critical for epidermal growth
factor (EGF) receptor (EGFR) and ErbB2 transactivation. (a and b) Serum-starved MDA-
MB-231 cells were pretreated with 100 ng/ml pertussis toxin for 18 h at 37 °C or left untreated
and then incubated in the absence or presence of 10 nM thrombin for 5 or 30 min at 37 °C.
Cells were processed and EGFR and ErbB2 tyrosine phosphorylation was measured as
described in Figure 1.
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Metalloprotease activity is required for thrombin-induced epidermal growth factor (EGF)
receptor (EGFR) and ErbB2 transactivation and cellular invasion. (a and b) Serum-deprived
MDA-MB-231 cells were preincubated with 0.1% dimethyl sulfoxide (DMSO) (vehicle
control), 10 µM GM6001 active or inactive agent for 1 h at 37 °C and then treated with or
without 10 nM thrombin for 5 min at 37 °C. EGFR and ErbB2 tyrosine phosphorylation was
detected as described in Figure 1. The data are expressed as fold increase over control and are
representative of three different experiments. (c) MDA-MB-231 cells were pretreated for 1 h
with 10 mM GM6001 active or inactive control agent then incubated with 1 pM thrombin at
37 °C. Cells were then added to the upper well and cellular invasion toward conditioned
medium (CM) containing inactive or active GM6001 was assessed. (d) Serum-starved MDA-
MB-231 cells were preincubated with 20 µg/ml of CRM 197, 100 ng/ml heparin or vehicle
control for 30 min at 37 °C and then treated in the absence (Ctrl) or presence of 10 nM Th or
16 nM EGF ligand for 5 min at 37 °C. ErbB tyrosine phosphorylation was then examined as
described above.
Arora et al. Page 19














Protease-activated receptor-1 (PAR10 mediates conditioned media-induced ErbB
transactivation and cellular invasion in vitro, and tumor growth in vivo. (a) The basal invasion
of control and PAR1-deficient P1 shRNA-expressing MDA-MB-231 cells toward NIH 3T3
fibroblast-conditioned medium (CM) was assessed. The data (mean ± s.d., n = 5) shown are
the number of invaded cells representative of at least three independent experiments. The
difference between invasion observed with control and PAR1-deficient MDA-MB-231 cells
was significant (***P<0.005). (b and c) Serum-deprived control and P1 shRNA-expressing
cells were incubated in the absence or presence of 10 nM thrombin, CM or 16 nM EGF for 8
min at 37 °C, and epidermal growth factor (EGF) receptor (EGFR) and ErbB2 tyrosine
phosphorylation was measured and quantified as described in Figure 1. The data shown are
expressed as fold increase over control and are representative of at least three independent
experiments. (d) PAR1-deficient and control MDA-MB-231 cells were implanted into the left
and right mammary fat pad of immunodeficient severe combined immunodeficiency (SCID)
mice, respectively. Tumor growth was measured weekly and the data (mean ± s.e., n = 3) are
Arora et al. Page 20













representative of two independent experiments. The difference between tumor size measured
in PAR1-deficient versus control MDA-MB-231 cell implants was significant (***P<0.005).
Tumors were excised from the mammary fat pads at 6-weeks postimplantation, fixed and
stained with hematoxylin and eosin (H&E) and imaged at ×1 and boxed areas at ×20
magnification and examined for morphology and the invasive edge.
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